TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of patients requiring invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Daily Calories Burned
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recruitment and Consent Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate and severity of (serious) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Individuals with at least 30% Pain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood lactate (bLa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in rate of perceived exertion (RPE)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of participants discontinued or lost to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Worsening of wound infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adverse drug reactions related to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Effective regurgitant orifice area (EROA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Geometric Mean Titer (GMT) of Antibodies for Influenza at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in GMT of Antibodies for SARS-CoV-2 at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: absolute lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Objective Response Rate (ORR) per Lugano Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with ≥1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants who Discontinue from Study Therapy Due to AE
Endpoint domain: Adverse events/effects
Primary endpoint: Serious Adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Event-free survival (EFS) of 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Critical threshold for motion adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal oxygen extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pulmonary ITV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in subaortic ITV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability: frequency and magnitude of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Peripheral blood CRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: POEM
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Video-based motion analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: assessment of tone using Ashworth scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue profile around the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ESKAPE reservoirs identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: GA lesion growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Time-to exhaustion during submaximal treadmill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ECG QTcF interval change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic and systolic blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood serotonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of life (QoL) of PLWHA
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in cognitive function-Global on RBANS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in cognitive function-Global on Covid-19 telephone battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline Maximal Voluntary Contraction at 72-hours post-exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle soreness (VAS) at 72-hours post-exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of messaging
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of major depression disorder
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of generalized anxiety disorder
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of painless hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in ODSI score from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Non-Invasive Tear Break-Up Time (NITBUT) from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of endolymphatic hydrops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Affect Balance Scale (PABS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postpartum Sleep Quality Scale (PSQS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reliability of images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of COM scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of stage I, II and III T1D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a relative increase in T cell richness or diversity of 20% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with a relative decrease in T cell clonality of 20% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of T cell richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Patients Achieving a Weight Loss of 5+% of Initial Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bilirubin decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Academic performance - grades
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients with and without fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum tolerated dose (MTD) for Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) for Consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose for expansion cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Closed Kinetic Chain Upper Extremity Stability Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Emraclidine and its Metabolite CV-0000364
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Last Specified Sampling Time (AUC0-t) of Emraclidine and its Metabolite CV-0000364
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Emraclidine and its Metabolite CV-0000364
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness (response to treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge level about family planning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with family planning services
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: [18F]FPIA uptake in mRCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to artefact appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASCVD risk estimated by the PCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the rate of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of Alofisel treatment versus fat grafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Extent of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphology of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biofilm pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Impact Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of patients that experience complications
Endpoint domain: Adverse events/effects
Primary endpoint: Photopic binocular distance corrected intermediate visual acuity (DCIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of early detection of cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cerebral function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measurement of patellofemoral indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PCr recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of access platform establishment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Typical Weekly Drinking at 1 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Frequency of Alcohol Consequences at 1 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Quantity/Frequency/Peak Alcohol Use at 1 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pembrolizumab Trough Concentration (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pembrolizumab Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Finger to floor test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Modified Thomas Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Detection of cancer in symptomatic individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of tumor tissue origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in composition of chemical analytes from the breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid core burden index (LCBI) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Burnout Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Valued Living
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Neuromuscular recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clickthrough rate to the online dashboard
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant anxiety symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant depression symptoms severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant quality of life and life satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants with Major Congenital Malformations
Endpoint domain: Adverse events/effects
Primary endpoint: Change of French-PAPA from baseline at 10 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BMI z score (child)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sleep Continuity- Time in Bed
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep Continuity- Sleep Onset Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep Continuity- Wake After Sleep Onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep Continuity- Sleep Efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Wake
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Detection of Daytime Sleep Periods
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of Adverse Event (AE) and Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Barium Swallow Study Impairment Profile Oral Total (MBSImP OT Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Restless Legs Syndrome Study Group rating scale (IRLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of better delineation of the biliary tree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in oral and gut microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of pancreatic fistula functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient Health Questionnaire 8-item scale (PHQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Revised Children's Anxiety and Depression Scale (RCADS) Parent Version (Short Form)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic accuracy for identifying AHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sixth finger illusion questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation between blood test results and colonoscopy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive and prognostic value of the KELIM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal RNA Virus Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in facial, submentum, and neck laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mammogram Uptake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Self-Injurious Behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Serious Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: PROMIS® Pain Interference change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants with Wins from the Hierarchical Unplanned stone treatment related healthcare utilization Composite Rank Score
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum transaminase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SportKat550 Kinesthetic Ability Trainer (SportKAT 550)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days alive and free from mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Turning ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular and Binocular Accommodative Facility (MAF/BAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective measures of visual comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: active ankle dorsiflexion range of motion (AROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in platelet levels (PLThigh - PLTlow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visual Analog Scale- VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discharge Readiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma levels of indoxyl sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of p-cresyl sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of indole-3-acetic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elapsed time to development of diabetes (T1D)
Endpoint domain: Mortality/survival
Primary endpoint: Ctrough of Lenacapavir (LEN) at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 26
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 26
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of different types of anterior and posterior circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein/albumin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neutrophil lymphocyte ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient decision for use of PARPi therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of Quick Reference Instructions (QRI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of the kit for home use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: accuracy of IUD position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: visibility of the threads of IUD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of patients with chronic diseases not offered educational program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reliability of the self-assessment questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EMG change from baseline after 2-week treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG change from baseline after 2-week treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Responder rates between groups
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of serious and non-serious adverse events between groups
Endpoint domain: Adverse events/effects
Primary endpoint: Time to treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician-assessed global disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported global disease activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: miRNA-93
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miRNA-412-3P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNB Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNA Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ANB Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASmin mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of any adverse events
Endpoint domain: Adverse events/effects